The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2017:

•        47 negotiations are currently underway with 6 new files added since the last update of July 31, 2017:
  • Brilinta (ticagrelor): Used with ASA to prevent atherothrombotic events with history of myocardial infarction
  • Descovy (emtricitabine/tenofovir alafenamide): Used to treat HIV-1 infection
  • Hemangiol (propranolol): Used to treat infantile hemangioma
  • Mictoryl (propiverine): Used to treat overactive bladder
  • Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide): Used to treat HIV-1 infection
  • Stivarga (regorafenib): Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST)

• 168 joint negotiations have been completed with 5 files successfully negotiated and 2 files closed as agreements were not reached since the last update of July 31, 2017:
  • Avastin (bevacizumab): Used to treat genitourinary platinum-resistant ovarian cancer (second letter of intent)
  • Avastin (bevacizumab): Used to treat metastatic colorectal cancer (second letter of intent)
  • Jakavi (ruxolitinib): Used to treat polycythemia vera (second letter of intent)
  • Butrans (buprenorphine): Used to treat persistent pain of moderate intensity
  • Caprelsa (vandetanib): Used to treat medullary thyroid cancer

Please Note: Negotiations involving Butrans and Caprelsa were closed as agreements were not reached.

• 54 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with 1 new file added since the last update of July 31, 2017:
  • Ninlaro (ixazomib): Used to treat multiple myeloma
• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of July 31, 2017.

For more information, please consult the pCPA’s website.